This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal. Athithi Verma August 27, 2026 Half the pot is split equally, so award size is a weak proxy for market size. Your buyer is a state rural health office, not… Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance. Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing. DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes Teva Faces New Probe in Turkey Over Conduct Flagged by EU Editor’s Pick In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part In Japan, Expanding a Label Is What Triggers the Price Cut AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.NeuroPulse NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It YetOrphanPulse OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029DealPulse Signal DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of ItDealPulse Report DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174BThe Beats DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the LeadAnalysis 7 Market Access Trends Reshaping Pharmaย by 2027 The Biologics Patent Cliff: Inside Pharma’s 2026-2029 ReckoningCoverage The ADC Decade Accelerates: What to Watch at ASCO 2026The Briefs This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal. Athithi Verma August 27, 2026 Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance. Athithi Verma August 27, 2026 Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing Athithi Verma August 27, 2026 A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing. Athithi Verma August 27, 2026 DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes Athithi Verma August 27, 2026 Teva Faces New Probe in Turkey Over Conduct Flagged by EU Athithi Verma August 27, 2026 Read More
This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal. Athithi Verma August 27, 2026 Half the pot is split equally, so award size is a weak proxy for market size. Your buyer is a state rural health office, not…
This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal. Athithi Verma August 27, 2026
Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance. Athithi Verma August 27, 2026
Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing Athithi Verma August 27, 2026
A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing. Athithi Verma August 27, 2026
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes Athithi Verma August 27, 2026